Isolated limb infusion: A review

Isolated limb perfusion is the preferred treatment option for locally advanced melanoma and sarcoma confined to a limb. This treatment results in high response rates with a satisfying duration of response in both tumours. A drawback of isolated limb perfusion, however, is the invasive and complex character of the procedure.

[1]  P. Kam,et al.  Isolated Limb Infusion for Melanoma , 2018, Cutaneous Melanoma.

[2]  P. Kam,et al.  Safety and Efficacy of Isolated Limb Infusion With Cytotoxic Drugs in Elderly Patients With Advanced Locoregional Melanoma , 2009, Annals of surgery.

[3]  P. Kam,et al.  Efficacy of repeat isolated limb infusion with melphalan and actinomycin D for recurrent melanoma , 2009, Cancer.

[4]  P. Kam,et al.  Factors Predictive of Acute Regional Toxicity After Isolated Limb Infusion with Melphalan and Actinomycin D in Melanoma Patients , 2009, Annals of Surgical Oncology.

[5]  F. Späh.  Inflammation in atherosclerosis and psoriasis: common pathogenic mechanisms and the potential for an integrated treatment approach , 2008, The British journal of dermatology.

[6]  P. Kam,et al.  Isolated Limb Infusion for Advanced Soft Tissue Sarcoma of the Extremity , 2008, Annals of Surgical Oncology.

[7]  R. Petersen,et al.  Isolated Limb Infusion for In-Transit Malignant Melanoma of the Extremity: A Well-Tolerated but Less Effective Alternative to Hyperthermic Isolated Limb Perfusion , 2008, Annals of Surgical Oncology.

[8]  P. Kam,et al.  Outcomes Following Isolated Limb Infusion for Melanoma. A 14-Year Experience , 2008, Annals of Surgical Oncology.

[9]  J. Zager,et al.  Toxicities associated with hyperthermic isolated limb perfusion and isolated limb infusion in the treatment of melanoma and sarcoma , 2008, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[10]  C. Augustine,et al.  Defining regional infusion treatment strategies for extremity melanoma: comparative analysis of melphalan and temozolomide as regional chemotherapeutic agents , 2007, Molecular Cancer Therapeutics.

[11]  P. Kam,et al.  Long-term Results of Hyperthermic, Isolated Limb Perfusion for Melanoma: A Reflection of Tumor Biology , 2007, Annals of surgery.

[12]  A. Eggermont,et al.  Safety and efficacy of isolated limb perfusion in elderly melanoma patients , 2002, Annals of Surgical Oncology.

[13]  P. Kam,et al.  Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma , 2002, Annals of Surgical Oncology.

[14]  PhD Kelly M. McMasters MD.  Isolated limb perfusion in elderly melanoma patients , 2007, Annals of Surgical Oncology.

[15]  R. Hegazi,et al.  Preoperative Isolated Limb Infusion of Doxorubicin and External Irradiation for Limb-Threatening Soft Tissue Sarcomas , 2007, Annals of Surgical Oncology.

[16]  Jeffrey E. Lee,et al.  Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  E. Egan,et al.  Isolated limb infusion with cytotoxic agent for treatment of localized refractory cutaneous T-cell lymphoma. , 2006, Clinical and laboratory haematology.

[18]  K. Brown,et al.  A Phase II Trial of Isolated Limb Infusion With Melphalan and Dactinomycin for Regional Melanoma and Soft Tissue Sarcoma of the Extremity , 2006, Annals of Surgical Oncology.

[19]  A. Eggermont,et al.  Isolated limb perfusion for melanoma patients—a review of its indications and the role of tumour necrosis factor-α , 2006 .

[20]  A. Eggermont,et al.  Repeat isolated limb perfusion with TNFalpha and melphalan for recurrent limb melanoma after failure of previous perfusion. , 2006, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[21]  O. Abdel-Wahab,et al.  Modulation of chemotherapy resistance in regional therapy: a novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic O6-benzylguanine , 2006, Molecular Cancer Therapeutics.

[22]  D. Damian,et al.  Treatment of Refractory Chromomycosis by Isolated Limb Infusion with Melphalan and Actinomycin D , 2006, Journal of cutaneous medicine and surgery.

[23]  A. V. van Geel,et al.  Isolated limb perfusion for melanoma patients--a review of its indications and the role of tumour necrosis factor-alpha. , 2006, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[24]  A. Eggermont,et al.  Efficacy of Repeat Isolated Limb Perfusions With Tumor Necrosis Factor α and Melphalan for Multiple In-Transit Metastases in Patients with Prior Isolated Limb Perfusion Failure , 2005, Annals of Surgical Oncology.

[25]  P. Kam,et al.  Isolated limb infusion with fotemustine after dacarbazine chemosensitisation for inoperable loco-regional melanoma recurrence. , 2004, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[26]  P. Kam,et al.  Isolated limb infusion for melanoma: A simple but effective alternative to isolated limb perfusion , 2004, Journal of surgical oncology.

[27]  F. Coevorden,et al.  Isolated Limb Perfusion: What Is the Evidence for Its Use? , 2004, Annals of Surgical Oncology.

[28]  H. Hoekstra,et al.  Hyperthermic isolated limb perfusion in the management of extremity sarcoma , 2003, Current opinion in oncology.

[29]  B. Kroon,et al.  Isolated limb perfusion for melanoma: technical aspects , 2003 .

[30]  A. Eggermont,et al.  Fifty Tumor Necrosis Factor–Based Isolated Limb Perfusions for Limb Salvage in Patients Older Than 75 Years With Limb-Threatening Soft Tissue Sarcomas and Other Extremity Tumors , 2003, Annals of surgical oncology.

[31]  B. Vrouenraets,et al.  Isolated limb perfusion for melanoma , 2002, Journal of surgical oncology.

[32]  J. Thompson,et al.  Pharmacokinetics and pharmacodynamics of melphalan in isolated limb infusion for recurrent localized limb malignancy , 2001, Melanoma research.

[33]  J. Wilt,et al.  Isolated Limb Perfusion in the Management of Patients With Recurrent Limb Melanoma: An Important but Limited Role , 2001, Annals of Surgical Oncology.

[34]  J. Thompson,et al.  Microdialysis and response during regional chemotherapy by isolated limb infusion of melphalan for limb malignancies , 2001, British Journal of Cancer.

[35]  M. Henderson,et al.  Isolated limb infusion for melanoma: a simple alternative to isolated limb perfusion. , 2001, Canadian journal of surgery. Journal canadien de chirurgie.

[36]  J. Bonenkamp,et al.  CASE REPORT Treatment of refractory hand warts by isolated limb infusion with melphalan and actinomycin D , 2001, The Australasian journal of dermatology.

[37]  P. Kam,et al.  Double isolated limb infusion with cytotoxic agents for recurrent and metastatic limb melanoma , 2001 .

[38]  A. Eggermont,et al.  Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study. , 1999, Melanoma research.

[39]  A. Eggermont,et al.  Relation between limb toxicity and treatment outcomes after isolated limb perfusion for recurrent melanoma. , 1999, Journal of the American College of Surgeons.

[40]  A. Eggermont,et al.  Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats , 1999, British Journal of Cancer.

[41]  A. Feldman,et al.  Management of Extremity Recurrences After Complete Responses to Isolated Limb Perfusion in Patients With Melanoma , 1999, Annals of Surgical Oncology.

[42]  W. Hohenberger,et al.  Pharmacokinetics of melphalan in isolated limb perfusion , 1999, Cancer Chemotherapy and Pharmacology.

[43]  B. Vrouenraets,et al.  Toxicity and morbidity of isolated limb perfusion. , 1998, Seminars in surgical oncology.

[44]  P. Kam,et al.  Isolated limb infusion with cytotoxic agents: a simple alternative to isolated limb perfusion. , 1998, Seminars in surgical oncology.

[45]  A. Eggermont,et al.  Isolated limb perfusion in primary and recurrent melanoma: indications and results. , 1998, Seminars in surgical oncology.

[46]  M. Roberts,et al.  Tissue and perfusate pharmacokinetics of melphalan in isolated perfused rat hindlimb. , 1997, The Journal of pharmacology and experimental therapeutics.

[47]  P. Kam,et al.  Frequency and duration of remission after isolated limb perfusion for melanoma. , 1997, Archives of surgery.

[48]  M. Roberts,et al.  Melphalan dosing regimens for management of recurrent melanoma by isolated limb perfusion: application of a physiological pharmacokinetic model based on melphalan distribution in the isolated perfused rat hindlimb , 1997, Melanoma research.

[49]  O. Merimsky,et al.  Synergism of tumor necrosis factor-alpha and melphalan in systemic and regional administration: animal study. , 1997, Invasion & metastasis.

[50]  P. Parsons,et al.  The effects of perfusion conditions on melphalan distribution in the isolated perfused rat hindlimb bearing a human melanoma xenograft. , 1997, British Journal of Cancer.

[51]  A. Eggermont,et al.  Synergistic effects of TNF-alpha and melphalan in an isolated limb perfusion model of rat sarcoma: a histopathological, immunohistochemical and electron microscopical study. , 1996, British Journal of Cancer.

[52]  B. Vrouenraets,et al.  Thirty‐five years of isolated limb perfusion for melanoma: Indications and results , 1996, The British journal of surgery.

[53]  A. Eggermont,et al.  Systemic toxicity after isolated limb perfusion with melphalan for melanoma. , 1996, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[54]  T. P. O’Connor,et al.  Soft tissue sarcoma of the extremity. , 1996, Annals of the Royal College of Surgeons of England.

[55]  P. Kam,et al.  Pharmacokinetics of melphalan during isolated limb infusion for melanoma , 1996 .

[56]  L. Skarsgard,et al.  The cytotoxicity of melphalan and its relationship to pH, hypoxia and drug uptake. , 1995, Anticancer research.

[57]  J. Beijnen,et al.  Melphalan tissue concentrations in patients treated with regional isolated perfusion for melanoma of the lower limb. , 1994, British Journal of Cancer.

[58]  A. Hart,et al.  Limb recurrence-free interval and survival in patients with recurrent melanoma of the extremities treated with normothermic isolated perfusion. , 1994, Journal of the American College of Surgeons.

[59]  P. Kam,et al.  Maximizing efficacy and minimizing toxicity in isolated limb perfusion for melanoma. , 1994, Melanoma research.

[60]  P. Kam,et al.  Isolated limb infusion with melphalan for recurrent limb melanoma : a simple alternative to isolated limb perfusion , 1994 .

[61]  C. Ingvar,et al.  The value of monitoring serum creatine phosphokinase following hyperthermic isolated limb perfusion for melanoma , 1993 .

[62]  A. Eggermont,et al.  Results of a double perfusion schedule with melphalan in patients with melanoma of the lower limb. , 1993, European journal of cancer.

[63]  G. Burnside,et al.  The pharmacokinetic advantages of isolated limb perfusion with melphalan for malignant melanoma. , 1992, British journal of cancer.

[64]  J. Klaase,et al.  Relation between calculated melphalan peak concentrations and toxicity in regional isolated perfusion for melanoma , 1992 .

[65]  M. Chapman,et al.  Effects of oxygenation and pH on tumor cell response to alkylating chemotherapy. , 1991, International journal of radiation oncology, biology, physics.

[66]  D. Chaplin,et al.  Potentiation of the tumor cytotoxicity of melphalan by vasodilating drugs. , 1989, International journal of radiation oncology, biology, physics.

[67]  K. Bland,et al.  A Phase II Study of the Efficacy of Diamminedichloroplatinum (Cisplatin) for the Control of Locally Recurrent and Intransit Malignant Melanoma of the Extremities Using Tourniquet Outflow‐Occlusion Techniques , 1989, Annals of surgery.

[68]  B. Kroon,et al.  Regional isolation perfusion in melanoma of the limbs; accomplishments, unsolved problems, future. , 1988, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[69]  A. V. van Geel,et al.  Regional perfusion treatment with melphalan for melanoma in a limb: an evaluation of drug kinetics. , 1988, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[70]  D. Alberts,et al.  A clinical and pharmacokinetic study of isolated limb perfusion with heat and melphalan for melanoma , 1985, Cancer.

[71]  E. V. van Slooten,et al.  Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. , 1982, European journal of cancer & clinical oncology.

[72]  C. Karakousis,et al.  Tourniquet Infusion Versus Hyperthermic Perfusion , 1982, Cancer.

[73]  C. Karakousis,et al.  Modes of regional chemotherapy. , 1979, The Journal of surgical research.

[74]  R. Fanelli.  Selective heat sensitivity of cancer cells , 1977 .

[75]  J. T. Grace.  Introductory statement: Cancer research in crisis , 1969 .

[76]  C. Heidelberger,et al.  Selective heat sensitivity of cancer cells. Biochemical and clinical studies , 1967 .